Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 7;6:24. doi: 10.1038/s41698-022-00263-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — The upper panels show ⁸⁹Zr-DFO-Sq -Durvalumab PET/CT imaging of NSG mouse bearing either HCC-827 PD-L1 high tumour (Panel A) or a low-to-non PD-L1 expressing A549 tumour (Panel B) at 144 h after PET tracer injection. Pseudo-coloured SUV overlays on CT scan maximum projection images are shown. Subcutaneous human tumour xenografts on right flanks are indicated by arrows. The lower panels show the same ⁸⁹Zr-durvalumab, as validated in the xenograft model, used for PET/CT imaging in a human subject with PD-L1 positive (90%) stage IV NSCLC. Over 6 days, sequential images show gradual accumulation of tracer in distant metastases. Axial PET/CT images (upper panels) show increasingly intensification of uptake in a vertebral body metastasis. Maximum intensity projection (MIP) images (lower panels) show blood pool imaging (day 1) and then gradual accumulation in metastatic disease, including lumbar spine and left hip. (Images courtesy of Dr Tim Akhurst, Peter MacCallum Cancer Centre).